Support Alert

Class 4 Medicines Defect Information: Rifadin (rifampicin) 150mg Capsules (MDR 127-09/19)

Aventis Pharma Limited t/a Sanofi has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that a change to the Patient Information Leaflet, concerning possible side effects for Rifadin (rifampicin) 150mg Capsules, has not been implemented by the required timeline.

Loading...

Email newsletter

Want the latest pharmacy news and updates straight to your inbox?

Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.

Sign Up